Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGT 501

Next Previous
Drug Profile

SGT 501

Alternative Names: SGT-501

Latest Information Update: 24 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solid Biosciences
  • Class Antiarrhythmics; Gene therapies
  • Mechanism of Action CASQ2 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polymorphic catecholergic ventricular tachycardia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Polymorphic catecholergic ventricular tachycardia

Most Recent Events

  • 01 Dec 2025 Phase-I clinical trials in Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in Canada (IV) (NCT07148089)
  • 01 Dec 2025 Phase-I clinical trials in Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT07148089)
  • 08 Sep 2025 Solid Biosciences plans the first-in-human phase Ib ARTEMIS trial for Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in USA (IV, Infusion), in October 2025 (NCT07148089),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top